company background image
A293780 logo

AptaBio Therapeutics KOSDAQ:A293780 Stock Report

Last Price

₩6.26k

Market Cap

₩168.3b

7D

-2.6%

1Y

-30.8%

Updated

26 Dec, 2024

Data

Company Financials

AptaBio Therapeutics Inc.

KOSDAQ:A293780 Stock Report

Market Cap: ₩168.3b

A293780 Stock Overview

A biopharmaceutical company, develops platform based drugs for intractable diseases. More details

A293780 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

AptaBio Therapeutics Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for AptaBio Therapeutics
Historical stock prices
Current Share Price₩6,260.00
52 Week High₩15,490.00
52 Week Low₩4,930.00
Beta2
1 Month Change-4.72%
3 Month Change-20.76%
1 Year Change-30.83%
3 Year Change-83.17%
5 Year Change-62.00%
Change since IPO-67.81%

Recent News & Updates

Recent updates

AptaBio Therapeutics (KOSDAQ:293780) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Oct 29
AptaBio Therapeutics (KOSDAQ:293780) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Is AptaBio Therapeutics (KOSDAQ:293780) Using Too Much Debt?

Jul 12
Is AptaBio Therapeutics (KOSDAQ:293780) Using Too Much Debt?

Here's Why AptaBio Therapeutics (KOSDAQ:293780) Can Manage Its Debt Despite Losing Money

Mar 26
Here's Why AptaBio Therapeutics (KOSDAQ:293780) Can Manage Its Debt Despite Losing Money

Do Institutions Own AptaBio Therapeutics Inc. (KOSDAQ:293780) Shares?

Feb 23
Do Institutions Own AptaBio Therapeutics Inc. (KOSDAQ:293780) Shares?

Companies Like AptaBio Therapeutics (KOSDAQ:293780) Can Afford To Invest In Growth

Jan 01
Companies Like AptaBio Therapeutics (KOSDAQ:293780) Can Afford To Invest In Growth

Shareholder Returns

A293780KR BiotechsKR Market
7D-2.6%-2.3%-1.9%
1Y-30.8%14.9%-9.5%

Return vs Industry: A293780 underperformed the KR Biotechs industry which returned 14.9% over the past year.

Return vs Market: A293780 underperformed the KR Market which returned -9.5% over the past year.

Price Volatility

Is A293780's price volatile compared to industry and market?
A293780 volatility
A293780 Average Weekly Movement7.8%
Biotechs Industry Average Movement8.8%
Market Average Movement6.6%
10% most volatile stocks in KR Market12.8%
10% least volatile stocks in KR Market3.3%

Stable Share Price: A293780 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A293780's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200932Jin Soowww.aptabio.com

AptaBio Therapeutics Inc., a biopharmaceutical company, develops platform based drugs for intractable diseases. Its platforms include Oxidative stress modulation platform for developing therapeutic agents for diabetes complications, vascular diseases, neurodegenerative diseases, and intractable cancers by controlling oxidative stress; Cancer-associated fibroblast control platform for developing new anticancer drugs for intractable cancer; and Aptamer-drug conjugate platform for developing intractable anticancer drugs with high unmet medical needs. The company offers Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX reagents for transfecting DNA or RNA into eukaryotic cells.

AptaBio Therapeutics Inc. Fundamentals Summary

How do AptaBio Therapeutics's earnings and revenue compare to its market cap?
A293780 fundamental statistics
Market cap₩168.28b
Earnings (TTM)-₩20.17b
Revenue (TTM)₩2.91b

57.9x

P/S Ratio

-8.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A293780 income statement (TTM)
Revenue₩2.91b
Cost of Revenue₩2.68b
Gross Profit₩226.00m
Other Expenses₩20.40b
Earnings-₩20.17b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-750.33
Gross Margin7.78%
Net Profit Margin-694.04%
Debt/Equity Ratio27.3%

How did A293780 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 19:59
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AptaBio Therapeutics Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Taehee KimMirae Asset Securities Co., Ltd.
Keunhee SeoSamsung Securities Co. Ltd.